



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/756,097

Confirmation No.: 5648

Applicant : MITCHELL et al.

Filed : January 8, 2001

TC/A.U. : 1623

Examiner : Unassigned

Docket No. : 027705.00013

Customer No. : 38485

For : METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME
MEDIATED RNA TRANS-SPLICING IN PLANTS

Commissioner for Patents

Date: June 29, 2006

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:


Pursuant to 37 C.F.R. §§1.97 and 1.98, applicants respectfully request that the documents listed on the accompanying PTO 1449 be considered by the Examiner and made of record in the above-referenced application.

Identification of the listed documents is not to be construed as an admission of the applicants or attorneys for applicants that such citations are available as "prior art" against the subject application. If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

Applicants believe that there is no fee required for this submission. However, if any fee is required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 01-2300 referencing Attorney Docket No. 027705.00013.

Respectfully submitted,


Rochelle K. Seide, Ph.D.
Registration No. 32,300
ARENT FOX PLLC
1675 Broadway
New York, NY 10019
Tel. No. (212) 484-3945
Fax No. (212) 484-3990
Customer No. 38485



Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.
	14	6,280,978	8/28/ 2001	Mitchell, et al.			
	15	6,083,702	7/4/ 2000	Mitchell, et al.			
	16	5,998,205	12/ 7/ 1999	Hallenbeck, et al.			
	17	5,962,313	10/5/1999	Podsakoff, et al.			
	18	5,962,311	10/ 5/ 1999	Wickham, et al.			
	19	5,952,221	9/14/ 1999	Kurtzman, et al.			
	20	5,932,210	8/ 3/ 1999	Gregory, et al.			
	21	5,928,944	7/27/ 1999	Seth, et al.			
	22	5,922,576	7/ 13/ 1999	He, et al.			
	23	5,919,676	7/ 6/ 1999	Graham, et al.			
	24	5,891,690	4/ 6/ 1999	Massie			
	25	5,885,808	3/ 23/ 1999	Spooner, et al.			
	26	5,877,011	3/2/ 1999	Armentano, et al.			
	27	5,871,982	2/ 16/ 1999	Wilson, et al.			

Examiner	Date Considered
----------	-----------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.
	28	5,869,037	2/ 9/ 1999	Crystal, et al.			
	29	5,858,351	1/ 12/ 1999	Podsakoff, et al.			
	30	5,851,806	12/ 22/ 1998	Kovesdi, et al.			
	31	5,843,742	12/ 1/ 1998	Natsoulis, et al.			
	32	5,837,484	11/ 17/ 1998	Trempe, et al.			
	33	5,820,868	10/ 13/ 1998	Mittal, et al.			
	34	5,789,390	8/ 4/ 1998	Descamps, et al.			
	35	5,756,283	5/26/ 1998	Wilson, et al.			
	36	5,747,072	5/ 5/ 1998	Davidson, et al.			
	37	5,731,172	3/ 24/ 1998	Saito, et al.			
	38	5,700,470	12/ 23/ 1997	Saito, et al.			
	39	5,670,488	9/ 23/ 1997	Gregory, et al.			
	40	5,616,326	4/1 1/ 1997	Spibey			
	41	5,589,377	12/ 31/ 1996	Lebkowski, et al.			
	42	5,585,362	12/ 17/ 1996	Wilson, et al.			

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

U.S. PATENT DOCUMENTS

Exam. Initial.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.
	43	5,354,678	10/ 11/ 1994	Lebkowski, et al.			
	44	4,980,286	12/ 25/ 1990	Morgan, et al.			
	151	6,013,487	1/11/00	Mitchell			

FOREIGN PATENT DOCUMENTS

Exam Initial	No.	Document No.	Date	Country	Class	Subclass	Translation Yes No
	102	WO 89/10134	11/02/89	PCT			
	110	WO 88/09810	12/15/88	PCT			
	152	WO 00/09734	2/24/00	PCT			
	153	WO 98/11241	3/19/98	PCT			

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	1	United States Patent Application Serial No. 10/693,192, filed October 23, 2003, "Screening Method for Identification of Efficient Pre-Trans-Splicing Molecules," Mitchell et al.
	2	United States Patent Application Serial No. 10/434,727, filed May 8, 2003, "Use of Slicesome Mediated RNA Trans-Splicing to Confer Cell Selective Replication to Adenoviruses," Otto et al.

Examiner	Date Considered
----------	-----------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	3	United States Patent Application Serial No. 10/374,784, filed February 25, 2003, "Trans-Splicing Mediated Imaging of Gene Expression," Mitchell et al.	
	4	United States Patent Application Serial No. 10/360,787, filed June 5, 2002, " Spliceosome Mediated RNA Trans-Splicing for Correction of Factor VIII Genetic Defects," Mitchell et al.	
	5	United States Patent Application Serial No. 10/198,447, filed July 17, 2002, "Spliceosome Mediated RNA Trans-Splicing for Correction of Skin Disorders," Mitchell et al.	
	6	United States Patent Application Serial No. 10/136,723, filed April 30, 2002, "Transgenic Animal Model for Spliceosome-mediated RNA Trans-Splicing," Puttaraju et al.	
	7	United States Patent Application Serial No. 10/103,294, filed March 20, 2002, "Spliceosome Mediated RNA Trans-Splicing," Mitchell et al.	
	8	United States Patent Application Serial No. 10/075,028, filed February 12, 2002, "Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing," Mitchell et al.	
	9	United States Patent Application Serial No. 10/076,248, filed February 12, 2002, "Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing," Mitchell et al.	
	10	United States Patent Application Serial No. 09/838,858, filed April 20, 2001, "Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing," Mansfield et al.	
	11	United States Patent Application Serial No. 09/756,097, filed Jan. 8, 2001, "Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing," Mitchell et al.	
	12	United States Patent Application Serial No. 09/756,095, filed Jan. 8, 2001, "Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing," Mitchell et al.	

Examiner	Date Considered
----------	-----------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	13	United States Patent Application Serial No. 09/756,096, filed Jan. 8, 2001, "Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing," Mitchell et al.	
	45	Bhaumik et al., "Molecular Imaging of Gene Expression in Living Subjects by Splicesome-Mediated RNA Trans-Splicing," June 8, 2004, Proc. Natl. Acad. Sci., 101:23:8693-8698.	
	46	Tahara et al., "Trans-Splicing Repair of CD40-Ligand Deficiency Results in Naturally Regulated Correction of A Mouse Model of Hyper-IgM X-Linked Immunodeficiency," August 2004, Nature Medicine, 10:835-841.	
	47	Chao et al., "Phenotype Correction of Hemophilia A Mice by Spliceosome-Mediated RNA Trans-Splicing," August 2003, Nature Medicine, 9:1-5.	
	48	Liu et al., "Partial Correction of Endogenous Δ508 CFTR in Human Cystic Fibrosis Airway Epithelia by Spliceosome-Mediated RNA Trans-Splicing," January 2002, Nature Biotechnology, 20:47-52.	
	49	Kim et al., "Role of the Nonsense-Mediated Decay Factor hUpf3 in the Splicing Dependent Exon-Exon Junction Complex," September 7, 2001, Science 293:1832-1836.	
	50	Kirn et al., "Replication-Selective Virotherapy for Cancer: Biological Principles, Risk Management and Future Directions," July 2001, Nat. Med. 7:781-787.	
	51	Tian et al., "Strong RNA Splicing Enhancers Identified by a Modified Method of Cycled Selection Interact with SR Protein," September 7, 2001, J. Biological Chemistry 276:33833-33839.	
	52	Mansfield et al., "Repair of CFTR mRNA by Splicesome-Mediated RNA Trans-Splicing," July 28, 2000, Gene Therapy 7:1885-1895.	
	53	Tacke et al., "Determinants of SR Protein Specificity," 1999, Curr. Opin. Cell Biol. 11:358-362.	
	54	He et al. "A Simplified System for Generating Recombinant Adenoviruses," March 1998, Proc. Natl. Acad. Sci., 95, 2509-2514.	

Examiner	Date Considered
----------	-----------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	55	Lan et al., "Ribozyme-Mediated Repair of Sickle β -Globin mRNAs in Erythrocyte Precursors" June 5, 1998, Science 280:1593-1596.	
	56	Phylactou et al., "Ribozyme-Mediated Trans-Splicing of a Trinucleotide Repeat" April 1998, Nature Genetics 18:378-381.	
	57	Staley et al., "Mechanical Devices of the Spliceosome: Motors, Clocks, Springs and Things," 1998, Cell 92:315-326.	
	58	Bellet et al., "Malignant Transformation of Nontrophoblastic Cells is Associated With the Expression of Chorionic Gonadotropin β Genes Normally Transcribed Introphoblastic Cells," February 1, 1997, Cancer Res. 57:516-523.	
	59	Coolidge et al., "Functional Analysis of The Polypyrimidine Tract in Pre-mRNA Splicing," 1997, Nucleic Acids Res. 25:888-896.	
	60	Crouzet et al. "Recombinational Construction in Escherichia Coli of Infectious Adenoviral Genomes," February 1997, Proc. Natl. Acad. Sci., 94, 1414-1419.	
	61	Good et al., "Expression of Small, Therapeutic RNAs in Human Cell Nuclei," 1997, Gene Ther. 4:45-54.	
	62	Malek et al., "Evolution of Trans-Splicing Plant Mitochondrial Introns in Pre-Permian Times," January 1997, Proc. Nat'l. Acad. Sci., 94:553-558.	
	63	Chartier, et al., "Efficient Generation of Recombinant Adenovirus Vectors by Homologous Recombination in Escherichia Coli," July 1996, Virol. 70, 4805-4810.	
	64	Hoon et al., "Detection of Metastatic Breast Cancer by β -hCG Polymerase Chain Reaction," 1996, Int J. Cancer 69:369-374.	
	65	Jone et al., "Tagging Ribozyme Reaction Sites to Follow Trans-Splicing in Mammalian Cells," June 1996, Nature Medicine 2:643-648.	

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	66	Krämer A., "The Structure and Function of Proteins Involved in Mammalian Pre-mRNA Splicing," 1996, Annu. Rev. Biochem. 65:367-409.	
	67	Miyake et al. "Efficient Generation of Recombinant Adenoviruses Using Adenovirus DNA-Terminal Protein Complex and A Cosmid Bearing the Full-Length Virus Genome," February 1996, Proc. Natl. Acad. Sci., 93, 1320-1324.	
	68	Nilsson et al., "Multiple Affinity Domains for the Detection, Purification, and Immobilization of Recombinant Proteins," 1996, J. Mol. Recognition, 9:585-594.	
	69	Pasman et al., "The 5' and 3' Splice Sites Come Together Via a Three Dimensional Diffusion Mechanism," 1996, Nucleic Acids Res. 24(9):1638-1645.	
	70	Boelens et al., "Nuclear Retention of RNA as a Mechanism for Localization" 1995, RNA 1:273-283.	
	71	Bruzik et al., "Enhancer-Dependent Interaction Between 5' and 3' Splice Sites in Trans," 1995, Proc. Nat'l. Acad. Sci., 92:7056-7059.	
	72	Chiara et al., "A Two-Step Mechanism for 5' and 3' Splice-Site Pairing," June 1995, Nature 375:510-513.	
	73	Davis et al., "RNA Trans-Splicing in Flatworms," September 15, 1995, J. Biol. Chem. 270:21813-21819.	
	74	Eul et al., "Experimental Evidence for RNA Trans-Splicing in Mammalian Cells," 1995, EMBO. J. 14(13):3226-3235.	
	75	Xiang-Dong Fu, "The Superfamily of Arginine/Serine-Rich Splicing Factors," 1995, RNA 1:663-680.	
	76	Bett et al. "An Efficient and Flexible System for Construction of Adenovirus Vectors with Insertions or Deletions in Early Regions 1 and 3," September 1994, Proc. Natl. Acad. Sci., 91,8802-8806.	
	77	Hollenberg et al., "Multiple Promoter Elements in the Human Chorionic Gonadotropin B Subunit Genes Distinguish their Expression from Luteinizing Hormone β Gene," 1994, Mol. Cell Endo., 106:111-119.	
	78	Ketner et al. "Efficient Manipulation of the Human Adenovirus Genome as an Infectious Yeast Artificial Chromosome Clone," June 1994, Proc. Natl. Acad. Sci., 91, 6186-6190.	

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	79	Sullenger et al., "Ribozyme-Mediated Repair of Defective mRNA by Targeted Trans-Splicing," October 1994, Nature 371:619-622.	
	80	Goldspiel et al., "Human Gene Therapy," July 1993, Clinical Pharmacy 12:488-505.	
	81	Kozarsky and Wilson et al., "Gene Therapy: Adenovirus Vectors," 1993, Current Opinion in Genetics and Development 3:499-503.	
	82	Miller and Rosman, "Use of Retroviral Vectors for Gene Transfer and Expression," 1993, Meth. Enzymol. 217:581-599.	
	83	Moore and Sharp, "Evidence for Two Active Sites in The Splicesome Provided by Stereochemistry of Pre-mRNA Splicing," September 23, 1993, The Nature, 365:364-368.	
	84	Moore et al, "Splicing of Precursors to mRNA by The Spliceosome," 1993, RNA World, 303-357.	
	85	Morgan and Anderson, "Human Gene Therapy," 1993, Ann. Rev. Biochem. 62:191-217.	
	86	Mulligan, Richard C., "The Basic Science of Gene Therapy," May 14, 1993, Science 260:926-932.	
	87	Roscigno et al., "A Mutational Analysis of the Polypyrimidine Tract of Introns," May 25, 1993, J. Bio. Chem., 268:11222-11229.	
	88	Tolstoshev, Paul, "Gene Therapy, Concepts, Current Trials, and Future Directions," 1993, Ann. Rev. Pharmacol. Toxicol. 33:573-596.	
	89	Acevedo et al., "Human Chorionic Gonadotropin-Beta Subunit Gene Expression in Cultured Human Fetal and Cancer Cells of Different Types and Origins," October 15, 1995, Cancer 76:1467-1475.	
	90	Bruzik et al., "Spliced Leader RNAs from Lower Eukaryotes are Trans-spliced in Mammalian Cells," December 1992, Nature 360:692-695.	
	91	Vellard et al., "A Potential Splicing Factor is Encoded by the Opposite Strand of The Trans-Spliced C-myb Exon," 1992, Proc. Nat'l. Acad. Sci., 89:2511-2515.	

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	92	Dingwall and Laskey, "Nuclear Targeting Sequences - A Consensus?" December 1991, Trends in Biochem. Sci., 16:478-481.	
	93	Ghaffas et al., "The Encephalomyocarditis Virus Internal Ribosome Entry Site Allows Efficient Coexpression of Two Genes from a Recombinant Provirus in Culture Cells and in Embryos," December 1991, Mol. Cell Biol. 11:5848-5859.	
	94	Janknecht et al., "Rapid and Efficient Purification of Native Histidine-Tagged Protein Expressed by Recombinant Vaccinia Virus," July 8, 1991, Proc. Natl. Acad. Sci., 88:8972-8976.	
	95	Rosenfeld et al. "Adenovirus-Mediated Transfer of a Recombinant α -1 Antitrypsin Gene to the Lung Epithelium in Vivo," April 19, 1991, Science, 252, 431-4.	
	96	Wu and Wu, "Delivery Systems for Gene Therapy," 1991, Biotherapy 3:87-95.	
	97	Gilardi et al. "Expression of Human α -1-Anti-trypsin Using a Recombinant Adenovirus Vector," 1990, EBS Lett. 267, 60-62.	
	98	Rajkovic et al., "A Spliced Leader is Present on a Subset of mRNAs from the Human Parasite Schistosoma Mansoni" November 1990, Proc. Nat'l. Acad. Sci., 87:8879-8883.	
	99	Schneider and Banes, "Building Blocks for Oligonucleotide Analogs with Dimethylene-Sulfide-Sulfoxide and Sulfone Groups Replacing Phosphodiester Linkages," 1990, Tet. Letters, 31:335-338.	
	100	Senapathy et al., "Splice Junctions, Branch Point Sites, and Exons:Sequence Statistics, Identification, and Applications to Genome Project," 1990, Methods In Enzymology, 183:252-278.	
	101	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," June 1990, Chemical Reviews, 90:543-584.	
	103	Kerem et al., "Identification of the Cystic Fibrosis Gene: Genetic Analysis," September 8, 1989, Science, 245:1073-1080.	
	104	Letsinger et al., "Cholestryl-Conjugated Oligonucleotide: Synthesis, Properties, and Activity as Inhibitors of Replication of Human Immunodeficiency Virus in Cell Culture," September 1989, Proc. Natl. Acad. Sci., 86:6553-6556.	

Examiner	Date Considered
----------	-----------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	105	Reed, Robin, "The Organization of 3' Splice Sites Sequences in Mammalian Introns," 1989, Genes Dev. 3:2113-2123.	
	106	Riordan et al., "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA," 1989, Science, 245:1066-1073.	
	107	Rommens et al., "Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping," September 8, 1989, Science, 245:1059-1065.	
	108	Shimizu et al., "Immunoglobulin Double-Isotype Expression by Trans-mRNA In a Human Immunoglobulin Transgenic Mouse," October 1989, Proc. Nat'l. Acad. Sci. 86:8020-8023.	
	109	Smith et al., "Scanning From an Independently Specified Branch Point Defines the 3' Splice Site of Mammalian Introns," 1989, Nature, 342:243-247.	
	111	Van der Krol et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences," 1988, BioTechniques, 6:958-976.	
	112	Reed & Maniatis, "The Role of The Mammalian Branchpoint Sequence In the Pre-mRNA Splicing," 1988, Genes Dev. 2:1268.	
	113	Smith et al, "Single-Step Purification of Polypeptides Expressed in Escherichia Coli as Fusions with Glutathione S-Transferase," 1988, Gene, 67:31.	
	114	Zon et al., "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," 1988, Pharm. Res., 5:539-549.	
	115	Krause M et al., "A Trans-Spliced Leader Sequence on Actin mRNA in C. Elegans," 1987, Cell 49:753-761.	
	116	Lemaitre et al., "Specific Antiviral Activity of a Poly(L-lysine)-Conjugated Oligodeoxyribonucleotide Sequence Complementary to Vesicular Stomatitis Virus N Protein mRNA Initiation Site," 1987, Proc. Natl. Acad. Sci., 84:648-652.	
	117	Wu and Wu, "Receptor-Mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," 1987, J. Biol. Chem., 262:429-4432.	
	118	Dingwall and Laskey, "Protein Import into the Cell Nucleus," 1986, Ann. Rev. Cell Biol. 2:367-390.	

Examiner	Date Considered
----------	-----------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	119	Murphy et al., "Identification of a Novel Y Branch Structure as an Intermediate in Trypanosome mRNA Processing: Evidence for Trans Splicing," 1986, Cell, 47:517.	
	120	Smith et al., "Mv 26,000 Antigen of Schistosoma Japonicum Recognized by Resistant WEH1 129/J Mice is a Parasite Glutathione S-Transferase," 1986, Proc. Natl. Acad. Sci., 83:8703-8707.	
	121	Sutton et al., "Evidence for Trans Splicing in Trypanosomes," 1986, Cell 47:527-535.	
	122	Konarska et al., "Trans Splicing of mRNA Precursors In Vitro" 1985, Cell 46:165-171.	
	123	Solnick et al, "Trans Splicing of mRNA Precursors," 1985, Cell 42:157-164.	
	124	Talmadge et al., "Only Three of the Seven Human Chorionic Gonadotropin Beta Subunit Genes can be Expressed in the Placenta," 1984, Nucleic Acids Res. 12:8415.	
	125	Accession No. K01722, Corynebacteriophage beta diphtheria toxin (DT) gene, April 27, 1993.	
	126	Berkner, et al. "Generation of Adenovirus by Transfection of Plasmids," 1983, Nucleic Acids Res. 11, 6003-6020.	
	127	Greenfield, "Nucleotide Sequence of the Structural Gene for the Diphtheria Toxin Carried by Corynebacteriophage β ," 1983, Proc. Natl. Acad. Sci., 80:6853-6857.	
	128	Brinster et al., "Regulation of Metallothionein-Thymidine Kinase Fusion Plasmids Injected into Mouse Eggs," 1982, Nature 296:39-42.	
	129	Benoist et al., "In Vivo Sequence Requirements of the SV40 Early Promoter Region," 1981, Nature, 290:304-310.	
	130	Wagner et al., "Nucleotide Sequence of the Thymidine Kinase Gene of Herpes Simplex Virus Type 1," March 1981, Proc. Natl. Acad. Sci., 78(3):1441-1445.	
	131	Yamamoto et al., "Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sarcoma Virus," 1980, Cell, 22:787-797.	

Examiner	Date Considered
----------	-----------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	132	Berget et al., "Spliced Segments at the 5' Terminus of Adenovirus 2 Late mRNA, 1977, Proc. Natl. Acad. Sci., 74(8):3171-3175.	
	133	Chow et al., "An Amazing Sequence Arrangement at the 5' Ends of Adenovirus 2 Messenger RNA," 1977, Cell 12:1-8.	
	134	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5," 1977, J. Gen. Virol. 36:59-72.	
	135	Uchida et al, "Diphtheria Toxin and Related Proteins: Isolation and Properties of Mutant Proteins Related to Diphtheria Toxin," 1973 J. Biol. Chem., 248:3838.	
	136	Puttaraju et al., Spliceosome-Mediated RNA Trans-Splicing as a Tool for Gene Therapy", Nat. Biotech., 1999, Vol. 17, 246-252.	
	137	Voss et al., "Efficiency Assessment of the Gene Trap Approach", 1998, Development Dynamics, 212:171-180.	
	138	Puttaraju et al., "Messenger RNA Repair and Restoration of Protein Function by Spliceosome-Mediated mRNA Trans-Splicing", Mol. Therapy, 2001, Vol. 4, 105-114.	
	139	Song et al., "Intramuscular Administration of Recombinant Adeno-Associated Virus 2 X-1 Antitrypsin (rAAV-SERPINA1) Vectors in a Nonhuman Primate Model: Safety and Immunologic Aspects", September 3, 2002, Molecular Therapy 6:329-335.	
	140	Garcia-Blanco et al, "Spliceosome-Mediated RNA Trans-Splicing in Gene Therapy and Genomics," April 20, 200, Gene Therapy and Regulation, 1:141-163.	
	141	Garcia-Blanco et al "Mending the Message", Nat. Biotech., 2003, Vol. 21, No. 12, 1448-1449.	
	142	Liu et al., "Spliceosome-Mediated RNA Trans-Splicing with Recombinant Adeno-Associated Virus Partially Restores Cystic Fibrosis Transmembrane Conductance Regulator Function to Polarized Human Cystic Fibrosis Airway Epithelial Cells," September 2005 Human Gene Therapy 16:1116-1123.	
	143	Mansfield, et al. "5' Exon Replacement and Repair by Spliceosome-Mediated RNA Trans-Splicing", RNA, 2003, Vol. 9, 1290-1297.	

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office		Atty. Docket No. (027705.00013)	Serial No. 09/756,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Mitchell et al.	
		Filing Date January 8, 2001	Group 1623
		Examiner Unassigned.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	144	Mansfield, et al., Repair of CFTR mRNA by Spliceosome-Mediated RNA Trans-Splicing", Gene Therapy, 2000, Vol. 7, 1885-1895.	
	145	Manzano, et al., "Failure to Generate Atheroprotective Apolipoprotein AI Phenotypes Using Synthetic RNA/DNA Oligonucleotides (chimeraplasts)", J. Gene Med., 2003, Vol. 5, 795-802.	
	146	Parolini, et al., "Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-I", J. Bio. Chem., 2003, Vol. 278, 4740-4746.	
	147	Martinez-Sales, E., "Internal Ribosome Entry Site Biology and Its Use In Expression Vectors, 1999, Current Opinion in Biology, 10:458-464.	
	148	Kikumori et al., "Promiscuity of Pre-mRNA Spliceosome-Mediated Trans Splicing: A Problem for Gene Therapy?", July 20, 2001, Human Gene Therapy, 12:1429-1441.	
	149	United States Patent Application Serial No. 09/941,492 filed August 29, 2001, "Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing," Mitchell et al.	
	150	United States Patent Application Serial No. 08/786,531 filed January 21, 1997, "Vehicles For Stable Transfer of Green Fluorescent Protein Gene And Methods of Use For Same," Link. Jr., et al.	

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYC/283224.1